Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

elbasvir / grazoprevir

Known as: ELBASVIR/GRAZOPREVIR, elbasvir and grazoprevir 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1… Expand
  • table 1
  • figure 1
  • figure 2
2019
2019
Treatment with all‐oral direct‐acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained… Expand
2019
2019
Background/Aims In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2019
2019
Despite highly effective direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients… Expand
2019
2019
Hepatitis C is a global health concern, with important implications in chronic kidney disease (CKD) due to its increased… Expand
Review
2018
Review
2018
Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated… Expand
2018
2018
Background and ObjectiveNew direct-acting antivirals (DAAs) have high efficacy and tolerability in the treatment of hepatitis C… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2017
Highly Cited
2017
BACKGROUND & AIMS Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2017
2017
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality… Expand
2016
2016
BACKGROUND & AIMS Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV… Expand
  • table 1
  • table 2
  • table 3